Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection

Haemostasis
W D Schleuning

Abstract

Plasminogen activators are enzymes found in all vertebrate species investigated so far. Their physiological function is the generation of localized proteolysis in the context of tissue remodeling, wound healing and neuronal plasticity. The common vampire bat (Desmodus rotundus) is a New World species that feeds exclusively on blood. Its saliva contains highly potent plasminogen activators, specialized in rapid lysis of fresh blood clots. Biochemical and pharmacological evidence indicates that these plasminogen activators represent a new class of thrombolytics with pharmacological and toxicological properties superior to human tissue-type plasminogen activator, the clot dissolving agent now most frequently used in medicine. A form of the enzyme produced by recombinant DNA technology is currently employed to test this hypothesis in clinical studies.

Citations

Sep 1, 2005·Journal of Thrombosis and Thrombolysis·Johannes J M L Hoffmann, Oliver Kops
Dec 3, 2013·Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology·Josmary BrazónCarmen L Arocha-Piñango
Feb 12, 2004·Insect Biochemistry and Molecular Biology·Weon-Kyoo YouKwang-Hoe Chung
Nov 5, 2003·CNS Drugs·Geoffrey A DonnanStephen M Davis
Nov 13, 2013·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Tongwei SuBin Bao
Aug 28, 2014·CNS Drugs·Kiyoshi KikuchiSalunya Tancharoen
Apr 28, 2005·Expert Review of Neurotherapeutics·H Christian SchumacherPhilip M Meyers
May 24, 2006·Expert Review of Cardiovascular Therapy·Nicole R Gonzales, James C Grotta
Jul 30, 2011·Expert Review of Neurotherapeutics·Muneer EesaPhilip M Meyers
Mar 16, 2007·Expert Opinion on Emerging Drugs·Paul A Lapchak, Dalia M Araujo
May 22, 2009·Expert Opinion on Biological Therapy·Maurizio PaciaroniJulien Bogousslavsky
Jul 12, 2008·Expert Opinion on Investigational Drugs·Paul A Lapchak
Jan 23, 2016·CNS Drugs·Nicola LogalloLars Thomassen
Nov 29, 2011·World Neurosurgery·Bernard R Bendok, Omar Arnaout
Dec 3, 2014·Enzyme and Microbial Technology·MohammadReza KazemaliFereidoun Mahboudi
Jun 2, 2011·British Journal of Pharmacology·Robert L Medcalf
Feb 12, 2015·Clinical Pharmacology and Therapeutics·P GurmanN M Elman
Jul 19, 2006·Drug Discovery Today·A Richard Green, Ashfaq Shuaib
Dec 11, 2013·Journal of Stroke·Andrew BivardMark W Parsonsb
Feb 12, 2013·Expert Opinion on Biological Therapy·Bartlomiej Piechowski-Jozwiak, Julien Bogousslavsky
Nov 20, 2002·Expert Opinion on Investigational Drugs·Paul A Lapchak
Apr 29, 2014·Expert Opinion on Investigational Drugs·Rikesh PatelStavros Apostolakis
Mar 14, 2012·Toxicon : Official Journal of the International Society on Toxinology·Rodrigo Ligabue-BraunCélia Regina Carlini
Mar 31, 2012·Circulation Research·Hannah V CareyDavid A Lathrop
Nov 15, 2014·Stroke; a Journal of Cerebral Circulation·Fabian DocagneDenis Vivien
Nov 21, 2009·Stroke; a Journal of Cerebral Circulation·Nishant K MishraKennedy R Lees
Apr 1, 2011·Annals of the New York Academy of Sciences·Thomas H KunzTheodore H Fleming

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.